Dr. Gajra on Adverse Effects Associated With CAR T-Cell Therapy in Hematologic Malignancies

Video

Ajeet Gajra, MD, FACP, discusses adverse effects associated with CAR T-cell therapy in hematologic malignancies.

Ajeet Gajra, MD, FACP, clinical professor of medicine, Upstate University Hospital, discusses adverse effects associated with CAR T-cell therapy in hematologic malignancies.

CAR T-cell therapy has garnered a lot of excitement in the hematologic malignancies space and continues to be introduced to new diseases, says Gajra. For example, on July 24, 2020, brexucabtagene autoleucel (Tecartus) received regulatory approval for patients with relapsed/refractory mantle cell lymphoma.

However, despite the encouraging data seen thus far, these products can cause toxicities such as cytokine release syndrome and immune effector cell-associated neurotoxicity syndrome.

Ultimately, additional research will assist in better defining the risk factors for these toxicities as well as developing safer products with less toxicities, Gajra concludes.

Newsletter

Stay at the forefront of cutting-edge science with CGT—your direct line to expert insights, breakthrough data, and real-time coverage of the latest advancements in cell and gene therapy.

Recent Videos
Derek Jackson, BS, MA, the vice president of cell & gene therapy product development at Pacira, and Kilian Guse, PhD, the vice president of genetic medicine platforms at Pacira
Derek Jackson, BS, MA, the vice president of cell & gene therapy product development at Pacira
Jeffrey Chamberlain, PhD
Tami John, MD
Tami John, MD
Tami John, MD
Matthew Ku, MBBS, FRACP, RACP, FRCPA/RCPA, PhD, an associate professor and the lymphoma stream lead at St Vincent’s Hospital
Saurabh Dahiya, MD, FACP, an associate professor of medicine at Stanford University School of Medicine; as well as clinical director of Cancer Cell Therapy in the Division of Blood and Marrow Transplantation and Cell Therapy at Stanford Medicine
Shahzad Raza, MD, a hematologist/oncologist at the Cleveland Clinic
Manali Kamdar, MD, the associate professor of medicine–hematology and clinical director of lymphoma services at the University of Colorado
Related Content
© 2025 MJH Life Sciences

All rights reserved.